TW200630374A - Thiazolyldihydroindazoles - Google Patents

Thiazolyldihydroindazoles

Info

Publication number
TW200630374A
TW200630374A TW094134894A TW94134894A TW200630374A TW 200630374 A TW200630374 A TW 200630374A TW 094134894 A TW094134894 A TW 094134894A TW 94134894 A TW94134894 A TW 94134894A TW 200630374 A TW200630374 A TW 200630374A
Authority
TW
Taiwan
Prior art keywords
thiazolyldihydroindazoles
pharmaceutical
excessive
producing
general formula
Prior art date
Application number
TW094134894A
Other languages
English (en)
Inventor
Bodo Betzemeier
Trixi Brandl
Steffen Breitfelder
Ralph Brueckner
Thomas Gerstberger
Michael Gmachl
Matthias Grauert
Frank Hilberg
Christoph Hoenke
Matthias Hoffmann
Maria Impagnatiello
Dirk Kessler
Christian Klein
Bernd Krist
Udo Maier
Darryl Mcconnell
Charlotte Reither
Stefan Scheuerer
Andreas Schoop
Norbert Schweifer
Oliver Simon
Martin Steegmaier
Steffen Steurer
Irene Waizenegger
Ulrike Weyer-Czernilofsky
Andreas Zoephel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004048877A external-priority patent/DE102004048877A1/de
Priority claimed from DE102005005813A external-priority patent/DE102005005813A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200630374A publication Critical patent/TW200630374A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
TW094134894A 2004-10-07 2005-10-06 Thiazolyldihydroindazoles TW200630374A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004048877A DE102004048877A1 (de) 2004-10-07 2004-10-07 PI3-Kinasen
DE102005005813A DE102005005813A1 (de) 2005-02-09 2005-02-09 PI3-Kinasen
EP05107230 2005-08-05

Publications (1)

Publication Number Publication Date
TW200630374A true TW200630374A (en) 2006-09-01

Family

ID=35448324

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134894A TW200630374A (en) 2004-10-07 2005-10-06 Thiazolyldihydroindazoles

Country Status (23)

Country Link
EP (1) EP1799690B1 (zh)
JP (1) JP5090914B2 (zh)
KR (1) KR20070113188A (zh)
CN (1) CN101035795B (zh)
AR (1) AR051743A1 (zh)
AT (1) ATE392425T1 (zh)
AU (1) AU2005293609B2 (zh)
BR (1) BRPI0518169A (zh)
CA (1) CA2579288A1 (zh)
CY (1) CY1108183T1 (zh)
DE (1) DE502005003777D1 (zh)
DK (1) DK1799690T3 (zh)
ES (1) ES2304022T3 (zh)
IL (1) IL182397A (zh)
MX (1) MX2007003802A (zh)
NZ (1) NZ554695A (zh)
PE (1) PE20060583A1 (zh)
PL (1) PL1799690T3 (zh)
PT (1) PT1799690E (zh)
SI (1) SI1799690T1 (zh)
TW (1) TW200630374A (zh)
UY (1) UY29149A1 (zh)
WO (1) WO2006040281A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645731A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
NZ572417A (en) * 2006-04-06 2011-12-22 Boehringer Ingelheim Int Thiazolyl dihydro-indazoles
AU2007233729A1 (en) * 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyldihydroindazole derivatives as protein kinase inhibitors
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
PE20080371A1 (es) 2006-05-19 2008-04-09 Wyeth Corp N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3
JP5258563B2 (ja) * 2006-06-29 2013-08-07 日産化学工業株式会社 αアミノ酸誘導体及びそれを有効成分として含む医薬
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
US8278313B2 (en) 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
UY31700A (es) 2008-03-13 2009-11-10 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
AU2009272033B2 (en) * 2008-07-17 2011-10-13 Asahi Kasei Pharma Corporation Nitrogenated heterocyclic compound
US8653097B2 (en) 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
EP2421872B1 (en) 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
US8288379B2 (en) * 2009-04-22 2012-10-16 Boehringer Ingelheim International Gmbh Thia-triaza-cyclopentazulenes
BR112012000035A2 (pt) 2009-07-02 2018-06-19 Novartis Ag 2-carboxamida cicloamino ureias, composição farmacêutica e uso dos referidos compostos
WO2012175522A1 (en) * 2011-06-21 2012-12-27 Novartis Ag Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
US20220289755A1 (en) * 2019-08-16 2022-09-15 Cyclacel Limited Process for the preparation of a pyrimidino-diazepine derivative
CN112876503B (zh) * 2021-03-18 2022-04-29 中国科学院兰州化学物理研究所 用于癌症硼中子俘获治疗药物的硼酸盐化合物及其制备

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6908932B2 (en) * 2001-10-24 2005-06-21 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
TWI314928B (en) * 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Also Published As

Publication number Publication date
CY1108183T1 (el) 2014-02-12
MX2007003802A (es) 2007-04-23
DK1799690T3 (da) 2008-06-30
PL1799690T3 (pl) 2008-09-30
JP5090914B2 (ja) 2012-12-05
IL182397A (en) 2011-11-30
EP1799690A1 (de) 2007-06-27
AU2005293609B2 (en) 2011-11-24
UY29149A1 (es) 2006-05-31
KR20070113188A (ko) 2007-11-28
IL182397A0 (en) 2007-07-24
WO2006040281A1 (de) 2006-04-20
BRPI0518169A (pt) 2008-11-04
CA2579288A1 (en) 2006-04-20
SI1799690T1 (sl) 2008-08-31
ATE392425T1 (de) 2008-05-15
NZ554695A (en) 2010-12-24
PE20060583A1 (es) 2006-08-17
CN101035795B (zh) 2012-03-21
AR051743A1 (es) 2007-02-07
DE502005003777D1 (de) 2008-05-29
CN101035795A (zh) 2007-09-12
AU2005293609A1 (en) 2006-04-20
JP2008515854A (ja) 2008-05-15
PT1799690E (pt) 2008-06-16
ES2304022T3 (es) 2008-09-01
EP1799690B1 (de) 2008-04-16

Similar Documents

Publication Publication Date Title
TW200630374A (en) Thiazolyldihydroindazoles
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
UA94944C2 (ru) 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла
TW200619218A (en) Pyrimidines as PLK inhibitors
TW200509892A (en) Novel aminobenzophenone compounds
UA95298C2 (ru) Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств
TW200607806A (en) Pyrimidines as plk inhibitors
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200621779A (en) Process for the manufacture of dihydropteridinones
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
WO2009003999A3 (en) Chemical compounds
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
GB0305152D0 (en) Organic compounds
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200612964A (en) Methods for preparing p2x7 inhibitors
TW200738659A (en) Novel compounds
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
TW200640911A (en) Novel, long acting betamimetics for the treatment of respiratory diseases
MY146802A (en) Novel drugs for treating respiratory diseases
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
MX2010009837A (es) Tiazolil-dihidro-indazoles.